Abstract |
Proliferative vitreoretinopathy, a disease process occurring in the setting of a rhegmatogenous retinal detachment, is thought to develop as a result of exposure of retinal cells to vitreous. Vitreous contains many growth factors, and platelet-derived growth factor (PDGF) has been considered a major contributor to PVR. Evaluation of both PDGF and PDGF receptors (PDGFRs) as potential therapeutic targets in the context of a rabbit model of PVR revealed that PDGFR-based approaches protected from PVR, whereas neutralizing PDGFs was a much less effective strategy. The basis for these observations appears to reflect that fact that the PDGFR could be activated by a wide spectrum of vitreal agents that are outside of the PDGF family. Furthermore, blocking signaling events by which the non-PDGFs indirectly activated PDGF alpha receptor ( PDGFRalpha) protected rabbits from developing PVR. These studies demonstrate that the best therapeutic targets for PVR are not PDGFs, but PDGFRalpha and certain signaling events required for indirectly activating PDGFRalpha.
|
Authors | Hetian Lei, Marc-Andre Rheaume, Andrius Kazlauskas |
Journal | Experimental eye research
(Exp Eye Res)
Vol. 90
Issue 3
Pg. 376-81
(Mar 2010)
ISSN: 1096-0007 [Electronic] England |
PMID | 19931527
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)
|
Chemical References |
- Platelet-Derived Growth Factor
- Receptor, Platelet-Derived Growth Factor alpha
|
Topics |
- Animals
- Disease Models, Animal
- Humans
- Platelet-Derived Growth Factor
(physiology)
- Rabbits
- Receptor, Platelet-Derived Growth Factor alpha
(metabolism)
- Retinal Detachment
(complications)
- Signal Transduction
(physiology)
- Vitreoretinopathy, Proliferative
(etiology, metabolism, prevention & control)
|